WebThe most common (incidence >30%, all grades) adverse events regardless of study drug relationship in the non–CNS3 ALL group were decreased white blood cell count (WBC; … WebIn the ITT population, the event rates were 54.8% for the atezolizumab plus bevacizumab group and 55.3% for the sunitinib group, and the overall survivals were 36.1 months (95% CI, 31.5-42.3 months) for the atezolizumab plus bevacizumab group and 35.3 months (95% CI, 28.6-42.1 months) for the sunitinib group.
Interim results from ZUMA-12: Axi-cel as frontline treatment for …
WebNov 13, 2024 · Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed … WebSep 1, 2024 · This analysis constitutes the first pre-specified OS IA; OS in the ITT population will be formally tested if DFS in that population reaches statistical significance at the final … philip chironis md
PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase …
WebApr 14, 2024 · Abstract. Introduction: TV, a tissue factor (TF)-directed antibody-drug conjugate, is approved under accelerated approval in the US at a dose of 2.0 mg/kg IV administered every 3 weeks (Q3W) for adult patients (pts) with recurrent or metastatic (r/m) cervical cancer who have progressed on or after chemotherapy. TV is also being … WebFeb 21, 2024 · Batch-wise data review. This approach is especially useful when data that require review are to be reviewed in a longitudinal manner (i.e. in order to review data obtained at visit 2 you need to also check data obtained at visit 1). This is often the case when the interim analysis should include patients who have reached a given relevant … WebApr 5, 2024 · Ardent Phase 2b Sickle Cell Disease Interim Analysis: The interim analysis for the Ardent trial was conducted when all participants completed the week 24 assessment or terminated early. The intent ... philip chism 2022